Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 19/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5428639 | 0.99 | ADRA1A (0.52) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL5426683 | 0.88 | HTR1A (0.41) | ADRA1AADRA1BADRA1D | |
| Hydrochloric Acid SCHEMBL5415275 | 0.88 | HTR1A (0.40) | ADRA1AADRA1BADRA1D | |
| SCHEMBL5426540 | 0.86 | HTR1A (0.44) | ADRA1AADRA1BADRA1D | |
| SCHEMBL5420326 | 0.86 | ADRA1A (0.41) | ADRA1AADRA1BADRA1D | |
| Hydrochloric Acid SCHEMBL5422403 | 0.86 | HTR1A (0.43) | ADRA1AADRA1BADRA1D | |
| Hydrochloric Acid SCHEMBL5436836 | 0.85 | ADRA1A (0.41) | ADRA1AADRA1BADRA1D | |
| SCHEMBL5433029 | 0.83 | HTR1A (0.46) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL5427772 | 0.83 | HTR1A (0.46) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL5418413 | 0.80 | HTR1A (0.46) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | claimed |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | ADRA1D, ADRA1A, ADRB1 | ADRA1A 2/4885ADRA1B 4/4885ADRA1D 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.